IL37 and psoriasis vulgaris: Guselkumab is the first biologic drug available that specifically inhibits IL‐23 downstream intercellular signaling by binding to its p19 subunit; it is approved for patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.